Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Ford Motor Company (F) Price & Performance

ADMA Biologics IncTrade
Ford Motor CompanyTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Ford Motor Company — how do they compare? ADMA Biologics Inc trades at $9.95 (market cap $2.22B), while Ford Motor Company trades at $13.83 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 25.1× ADMA Biologics Inc's market cap, and Ford Motor Company pays a 4.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAF
Market Cap
$2.22B$55.75B
Sector
HealthConsumer Cyclical
52-Week High
$20.38$17.44
52-Week Low
$7.60$11.21
Enterprise Value
$2.29B$187.71B
Dividend Yield
4.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Ford Motor Company

Ford Motor Company (F) trades at $14.015, up 0.25% on the day, with a bearish technical signal and mixed earnings history including a recent Q3 2026 miss. The company reported a net loss of $8.18 billion for 2025, with negative profit margins, but maintains strong operating cash flow of $21.28 billion. Recent news highlights the upcoming affordable Fathom EV truck priced around $28,000, targeting market share gains amid high vehicle prices.

The outlook is cautious; while analyst consensus is a Buy with a $16.18 price target, fundamental weaknesses like negative ROE and net income margin pose risks. The EV transition and competitive pressures are key challenges, but the dividend yield and cash flow stability offer some investor appeal. Execution on new models like the Fathom is critical for a turnaround.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Ford Motor Company

Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.

Read more on F